Increasing evidence indicates that human endogenous retroviruses (HERVs) are important to human health and are an underexplored component of many diseases. Certain HERV families show unique expression patterns and immune responses in autism spectrum disorder (ASD) patients compared to healthy controls, suggesting their potential as biomarkers. Despite these interesting findings, the role of HERVs in ASD needs to be further investigated. In this review, we discuss recent advances in genetic research on ASD, with a particular emphasis on the implications of HERVs on neurodevelopment and future genomic initiatives aimed at discovering ASD-related genes through Artificial Intelligence. Given their pro-inflammatory and autoimmune characteristics, the existing literature suggests that HERVs may contribute to the onset or worsening of ASD in individuals with a genetic predisposition. Therefore, we propose that investigating their fundamental properties could not only improve existing therapies but also pave the way for new therapeutic strategies.
Background: Human endogenous retrovirus K (HERV-K, HML-2) is among the most transcriptionally active endogenous retroviral families and has been implicated in breast cancer (BC) pathogenesis. This study aimed to explore HERV-K (HML-2)-associated env expression and evaluate its utility as a potential non-invasive circulating biomarker for BC. Methods: Public RNA-seq data from breast epithelial transformation models (GSE84275) were screened to identify dysregulated HERV-K (HML-2)-associated env signals. An upregulated HERV-K (HML-2)-associated env signal overlapping the chromosome 4p16.1 region was prioritized for clinical evaluation. Peripheral family-level HERV-K (HML-2)-associated env expression was subsequently quantified by quantitative real-time PCR (qRT-PCR) in peripheral blood leukocytes obtained from 56 BC patients and 45 healthy controls. Results: Peripheral HERV-K (HML-2)-associated env expression was significantly higher in BC patients than in healthy controls (median: 0.9111 vs. 0.5284, P = 0.0003). Receiver operating characteristic (ROC) curve analysis demonstrated moderate discriminatory performance (area under the curve [AUC] = 0.7075, 95% CI: 0.6051–0.8100, P = 0.0005). Expression levels were significantly elevated in early-stage disease (stages I–IIA) compared with advanced stages (P < 0.0001). Multivariable logistic regression analysis confirmed that elevated env-associated expression remained an independent predictor of BC (adjusted OR = 12.66, 95% CI: 3.14–51.02, P < 0.001). Conclusions: Elevated peripheral HERV-K (HML-2)-associated env expression represents a circulating molecular signal prominently associated with early-stage breast cancer, highlighting its potential utility as a complementary non-invasive diagnostic biomarker.